bluebird bio, Inc. (BLUE)
USD 3.95
(-2.47%)
USD 3.95
(-2.47%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 424.62 Million USD | 18.43% |
| 2022 | 358.55 Million USD | 63.34% |
| 2021 | 219.51 Million USD | -48.49% |
| 2020 | 426.19 Million USD | -3.67% |
| 2019 | 442.43 Million USD | 23.66% |
| 2018 | 357.77 Million USD | 29.1% |
| 2017 | 277.13 Million USD | 11.44% |
| 2016 | 248.68 Million USD | 63.78% |
| 2015 | 151.84 Million USD | 131.88% |
| 2014 | 65.48 Million USD | -9.96% |
| 2013 | 72.72 Million USD | -41.85% |
| 2012 | 125.06 Million USD | 44.38% |
| 2011 | 86.62 Million USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 500.43 Million USD | 17.85% |
| 2024 Q2 | 492.21 Million USD | -1.64% |
| 2023 Q4 | 424.62 Million USD | 8.58% |
| 2023 FY | 424.62 Million USD | 18.43% |
| 2023 Q3 | 391.07 Million USD | 4.46% |
| 2023 Q1 | 337.99 Million USD | -5.73% |
| 2023 Q2 | 374.37 Million USD | 10.76% |
| 2022 FY | 358.55 Million USD | 63.34% |
| 2022 Q4 | 358.55 Million USD | -0.74% |
| 2022 Q1 | 227.81 Million USD | 3.78% |
| 2022 Q3 | 361.24 Million USD | -8.19% |
| 2022 Q2 | 393.47 Million USD | 72.72% |
| 2021 FY | 219.51 Million USD | -48.49% |
| 2021 Q1 | 436.94 Million USD | 2.52% |
| 2021 Q2 | 469.89 Million USD | 7.54% |
| 2021 Q3 | 469.11 Million USD | -0.17% |
| 2021 Q4 | 219.51 Million USD | -53.21% |
| 2020 Q3 | 422.46 Million USD | -0.77% |
| 2020 Q2 | 425.75 Million USD | 4.18% |
| 2020 Q1 | 408.67 Million USD | -7.63% |
| 2020 Q4 | 426.19 Million USD | 0.88% |
| 2020 FY | 426.19 Million USD | -3.67% |
| 2019 Q2 | 386.97 Million USD | 5.58% |
| 2019 Q1 | 366.51 Million USD | 2.44% |
| 2019 Q3 | 420.5 Million USD | 8.67% |
| 2019 FY | 442.43 Million USD | 23.66% |
| 2019 Q4 | 442.43 Million USD | 5.21% |
| 2018 Q3 | 350.99 Million USD | 15.47% |
| 2018 Q4 | 357.77 Million USD | 1.93% |
| 2018 Q2 | 303.97 Million USD | 2.48% |
| 2018 Q1 | 296.6 Million USD | 7.03% |
| 2018 FY | 357.77 Million USD | 29.1% |
| 2017 Q2 | 257.11 Million USD | -0.03% |
| 2017 FY | 277.13 Million USD | 11.44% |
| 2017 Q3 | 264.43 Million USD | 2.85% |
| 2017 Q4 | 277.13 Million USD | 4.8% |
| 2017 Q1 | 257.19 Million USD | 3.42% |
| 2016 Q4 | 248.68 Million USD | 11.14% |
| 2016 FY | 248.68 Million USD | 63.78% |
| 2016 Q3 | 223.74 Million USD | 22.68% |
| 2016 Q2 | 182.37 Million USD | 5.91% |
| 2016 Q1 | 172.19 Million USD | 13.41% |
| 2015 Q2 | 80.2 Million USD | 35.21% |
| 2015 Q1 | 59.31 Million USD | -9.41% |
| 2015 FY | 151.84 Million USD | 131.88% |
| 2015 Q4 | 151.84 Million USD | 18.04% |
| 2015 Q3 | 128.63 Million USD | 60.39% |
| 2014 Q4 | 65.48 Million USD | -4.13% |
| 2014 Q3 | 68.3 Million USD | -8.77% |
| 2014 Q1 | 65.34 Million USD | -10.15% |
| 2014 Q2 | 74.86 Million USD | 14.57% |
| 2014 FY | 65.48 Million USD | -9.96% |
| 2013 Q2 | 73.27 Million USD | -7.2% |
| 2013 Q3 | 70.56 Million USD | -3.7% |
| 2013 Q4 | 72.72 Million USD | 3.06% |
| 2013 FY | 72.72 Million USD | -41.85% |
| 2013 Q1 | 78.95 Million USD | -36.87% |
| 2012 Q4 | 125.06 Million USD | 0.0% |
| 2012 FY | 125.06 Million USD | 44.38% |
| 2011 FY | 86.62 Million USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Absci Corporation | 58.3 Million USD | -628.293% |
| Adaptive Biotechnologies Corporation | 352.85 Million USD | -20.339% |
| Alnylam Pharmaceuticals, Inc. | 4.05 Billion USD | 89.517% |
| Alzamend Neuro, Inc. | 3.22 Million USD | -13063.481% |
| Apollomics, Inc. | 14.15 Million USD | -2900.24% |
| 180 Life Sciences Corp. | 5.38 Million USD | -7782.078% |
| Atossa Therapeutics, Inc. | 5.23 Million USD | -8009.702% |
| Bicycle Therapeutics plc | 224.41 Million USD | -89.216% |
| Barinthus Biotherapeutics plc | 27.51 Million USD | -1443.47% |
| BioXcel Therapeutics, Inc. | 130.21 Million USD | -226.107% |
| CASI Pharmaceuticals, Inc. | 51.1 Million USD | -730.918% |
| Chimerix, Inc. | 19.74 Million USD | -2050.539% |
| CRISPR Therapeutics AG | 346.76 Million USD | -22.452% |
| Contineum Therapeutics, Inc. Class A Common Stock | 198.32 Million USD | -114.108% |
| EyePoint Pharmaceuticals, Inc. | 88.86 Million USD | -377.852% |
| Fortress Biotech, Inc. | 165.93 Million USD | -155.892% |
| Fortress Biotech, Inc. | 165.93 Million USD | -155.892% |
| Gritstone bio, Inc. | 125.91 Million USD | -237.22% |
| Allakos Inc. | 74.79 Million USD | -467.732% |
| Boundless Bio, Inc. Common Stock | 256.97 Million USD | -65.239% |
| Cara Therapeutics, Inc. | 68.75 Million USD | -517.554% |
| Cytokinetics, Incorporated | 1.21 Billion USD | 64.926% |
| enGene Holdings Inc. Common Stock | 14.47 Million USD | -2833.905% |
| Innoviva, Inc. | 568.55 Million USD | 25.315% |
| Hoth Therapeutics, Inc. | 704.98 Thousand USD | -60131.807% |
| NLS Pharmaceutics AG | 10.68 Million USD | -3875.804% |
| RAPT Therapeutics, Inc. | 26.29 Million USD | -1514.908% |
| Salarius Pharmaceuticals, Inc. | 1.29 Million USD | -32582.466% |
| Terns Pharmaceuticals, Inc. | 13.15 Million USD | -3129.08% |
| Vigil Neuroscience, Inc. | 24.6 Million USD | -1625.693% |
| ImmuCell Corporation | 18.81 Million USD | -2156.835% |
| IDEAYA Biosciences, Inc. | 28.22 Million USD | -1404.372% |
| Incyte Corporation | 1.59 Billion USD | 73.332% |
| Inovio Pharmaceuticals, Inc. | 55.59 Million USD | -663.777% |
| Lexaria Bioscience Corp. | 403.9 Thousand USD | -105028.891% |
| Mustang Bio, Inc. | 17.61 Million USD | -2310.035% |
| MiMedx Group, Inc. | 96.33 Million USD | -340.801% |
| MEI Pharma, Inc. | 8.35 Million USD | -4982.274% |
| MacroGenics, Inc. | 154.2 Million USD | -175.36% |
| Monopar Therapeutics Inc. | 1.75 Million USD | -24062.154% |
| Mereo BioPharma Group plc | 15.96 Million USD | -2560.218% |
| Marker Therapeutics, Inc. | 3.07 Million USD | -13709.593% |
| Marinus Pharmaceuticals, Inc. | 154.14 Million USD | -175.474% |
| Maravai LifeSciences Holdings, Inc. | 697.56 Million USD | 39.128% |
| Minerva Neurosciences, Inc. | 85.35 Million USD | -397.462% |
| NeuroBo Pharmaceuticals, Inc. | 6.09 Million USD | -6865.617% |
| NeuroSense Therapeutics Ltd. | 5.05 Million USD | -8308.396% |
| NextCure, Inc. | 14.99 Million USD | -2731.393% |
| Orchestra BioMed Holdings, Inc. | 27.16 Million USD | -1462.899% |
| Ocuphire Pharma, Inc. | 4.04 Million USD | -10405.294% |
| Onconetix, Inc. | 23.18 Million USD | -1731.785% |
| Oncternal Therapeutics, Inc. | 6.67 Million USD | -6259.503% |
| Opthea Limited | 264.6 Million USD | -60.477% |
| Ovid Therapeutics Inc. | 56.22 Million USD | -655.157% |
| Psyence Biomedical Ltd. | 12.1 Million USD | -3407.927% |
| PDS Biotechnology Corporation | 33.25 Million USD | -1176.714% |
| Precigen, Inc. | 41.64 Million USD | -919.652% |
| Pieris Pharmaceuticals, Inc. | 11.92 Million USD | -3461.684% |
| Prime Medicine, Inc. | 60.78 Million USD | -598.625% |
| PureTech Health plc | 125.58 Million USD | -238.122% |
| Rocket Pharmaceuticals, Inc. | 73.76 Million USD | -475.629% |
| Regeneron Pharmaceuticals, Inc. | 7.1 Billion USD | 94.025% |
| Replimune Group, Inc. | 113.21 Million USD | -275.063% |
| Revelation Biosciences, Inc. | 5.56 Million USD | -7530.406% |
| Rigel Pharmaceuticals, Inc. | 145.86 Million USD | -191.1% |
| TransCode Therapeutics, Inc. | 3.52 Million USD | -11932.802% |
| Revolution Medicines, Inc. Warrant | 262.39 Million USD | -61.825% |
| Reviva Pharmaceuticals Holdings, Inc. | 6.6 Million USD | -6326.609% |
| Sesen Bio, Inc. | 30.98 Million USD | -1270.462% |
| Sangamo Therapeutics, Inc. | 82.43 Million USD | -415.114% |
| Solid Biosciences Inc. | 38.45 Million USD | -1004.124% |
| Syndax Pharmaceuticals, Inc. | 58.68 Million USD | -623.577% |
| SciSparc Ltd. | 1.59 Million USD | -26522.194% |
| Sutro Biopharma, Inc. | 321.08 Million USD | -32.246% |
| TG Therapeutics, Inc. | 169.08 Million USD | -151.13% |
| Tonix Pharmaceuticals Holding Corp. | 48.93 Million USD | -767.784% |
| Titan Pharmaceuticals, Inc. | 1.44 Million USD | -29306.094% |
| Travere Therapeutics, Inc. | 588.1 Million USD | 27.798% |
| UroGen Pharma Ltd. | 243.52 Million USD | -74.367% |
| Verrica Pharmaceuticals Inc. | 61.83 Million USD | -586.716% |
| XOMA Corporation | 145.58 Million USD | -191.677% |
| Zentalis Pharmaceuticals, Inc. | 124.63 Million USD | -240.691% |
| AbCellera Biologics Inc. | 335.77 Million USD | -26.46% |
| Longboard Pharmaceuticals, Inc. | 9.77 Million USD | -4244.424% |
| Cassava Sciences, Inc. | 14.19 Million USD | -2891.363% |
| Corbus Pharmaceuticals Holdings, Inc. | 35.17 Million USD | -1107.103% |
| Precision BioSciences, Inc. | 140.92 Million USD | -201.323% |
| Dyadic International, Inc. | 2.34 Million USD | -18041.278% |
| Intensity Therapeutics, Inc. | 4.13 Million USD | -10173.99% |
| Eton Pharmaceuticals, Inc. | 16.26 Million USD | -2510.982% |
| VYNE Therapeutics Inc. | 8.95 Million USD | -4644.402% |
| Tenaya Therapeutics, Inc. | 31.09 Million USD | -1265.746% |
| IGM Biosciences, Inc. | 220.17 Million USD | -92.856% |
| X4 Pharmaceuticals, Inc. | 96.15 Million USD | -341.585% |
| Acelyrin, Inc. | 86.35 Million USD | -391.73% |
| Abeona Therapeutics Inc. | 49.17 Million USD | -763.478% |
| Ligand Pharmaceuticals Incorporated | 130.7 Million USD | -224.867% |
| Inhibikase Therapeutics, Inc. | 3.52 Million USD | -11933.355% |
| Arcturus Therapeutics Holdings Inc. | 150.88 Million USD | -181.415% |
| Syros Pharmaceuticals, Inc. | 151.51 Million USD | -180.258% |
| Senti Biosciences, Inc. | 52.57 Million USD | -707.715% |
| Mesoblast Limited | 188.79 Million USD | -124.909% |
| Kymera Therapeutics, Inc. | 180.78 Million USD | -134.874% |
| ChromaDex Corporation | 26.5 Million USD | -1501.871% |
| BriaCell Therapeutics Corp. | 8.55 Million USD | -4862.188% |
| Akebia Therapeutics, Inc. | 272.28 Million USD | -55.947% |
| Dermata Therapeutics, Inc. | 1.62 Million USD | -26052.982% |
| Seer, Inc. | 39.36 Million USD | -978.684% |
| Xeris Biopharma Holdings, Inc. | 347.58 Million USD | -22.166% |
| Novavax, Inc. | 2.57 Billion USD | 83.492% |
| Virpax Pharmaceuticals, Inc. | 7.69 Million USD | -5418.881% |
| Fate Therapeutics, Inc. | 137.8 Million USD | -208.145% |
| Checkpoint Therapeutics, Inc. | 18.42 Million USD | -2204.608% |
| Lyell Immunopharma, Inc. | 95.07 Million USD | -346.611% |
| Celcuity Inc. | 51.45 Million USD | -725.313% |
| ContextLogic Inc. | 206 Million USD | -106.128% |
| Phathom Pharmaceuticals, Inc. | 486.6 Million USD | 12.737% |
| HOOKIPA Pharma Inc. | 71.48 Million USD | -494.046% |
| Jazz Pharmaceuticals plc | 7.65 Billion USD | 94.454% |
| Amarin Corporation plc | 279.58 Million USD | -51.875% |
| AnaptysBio, Inc. | 364.28 Million USD | -16.563% |
| Aptevo Therapeutics Inc. | 12.62 Million USD | -3264.424% |
| Aptorum Group Limited | 5.25 Million USD | -7977.709% |
| Cartesian Therapeutics, Inc. | 745.23 Million USD | 43.021% |
| Arrowhead Pharmaceuticals, Inc. | 478.39 Million USD | 11.239% |
| Ardelyx, Inc. | 130.76 Million USD | -224.728% |
| Celularity Inc. | 102.92 Million USD | -312.541% |
| Omeros Corporation | 403.25 Million USD | -5.3% |
| Humacyte, Inc. | 114.67 Million USD | -270.278% |
| Immunocore Holdings plc | 228.15 Million USD | -86.11% |
| IO Biotech, Inc. | 17.55 Million USD | -2318.683% |
| GT Biopharma, Inc. | 6.63 Million USD | -6301.689% |
| Cabaletta Bio, Inc. | 17.45 Million USD | -2333.096% |
| Summit Therapeutics Inc. | 125.25 Million USD | -239.002% |
| Alaunos Therapeutics, Inc. | 1.95 Million USD | -21608.793% |
| Pulmatrix, Inc. | 15.96 Million USD | -2560.051% |
| Intellia Therapeutics, Inc. | 250.8 Million USD | -69.302% |
| Evogene Ltd. | 17.99 Million USD | -2260.334% |
| CorMedix Inc. | 11.91 Million USD | -3463.021% |
| BioLineRx Ltd. | 50.7 Million USD | -737.49% |
| VistaGen Therapeutics, Inc. | 9.36 Million USD | -4433.191% |
| Sagimet Biosciences Inc. | 5.65 Million USD | -7410.152% |
| PTC Therapeutics, Inc. | 2.72 Billion USD | 84.399% |
| scPharmaceuticals Inc. | 57.26 Million USD | -641.559% |
| Fulcrum Therapeutics, Inc. | 22.5 Million USD | -1787.134% |
| Corcept Therapeutics Incorporated | 114.81 Million USD | -269.843% |
| NLS Pharmaceutics AG | 10.68 Million USD | -3875.804% |
| Reviva Pharmaceuticals Holdings, Inc. | 6.6 Million USD | -6326.609% |
| Akero Therapeutics, Inc. | 44.96 Million USD | -844.343% |
| Eliem Therapeutics, Inc. | 2.87 Million USD | -14695.261% |
| Lisata Therapeutics, Inc. | 6.8 Million USD | -6144.471% |
| Stoke Therapeutics, Inc. | 68.77 Million USD | -517.392% |
| Reneo Pharmaceuticals, Inc. | 18.82 Million USD | -2155.519% |
| Outlook Therapeutics, Inc. | 46.73 Million USD | -808.5% |
| ProMIS Neurosciences, Inc. | 12.38 Million USD | -3327.698% |
| Daré Bioscience, Inc. | 26.32 Million USD | -1512.709% |
| BioMarin Pharmaceutical Inc. | 1.89 Billion USD | 77.534% |
| DBV Technologies S.A. | 42.8 Million USD | -892.112% |
| Avidity Biosciences, Inc. | 127.79 Million USD | -232.28% |
| Galecto, Inc. | 5.89 Million USD | -7101.9% |
| Sensei Biotherapeutics, Inc. | 9.47 Million USD | -4379.629% |
| Spruce Biosciences, Inc. | 27.43 Million USD | -1447.633% |
| Inhibrx Biosciences, Inc. | 264.39 Million USD | -60.605% |
| GlycoMimetics, Inc. | 6.9 Million USD | -6052.122% |
| Arcutis Biotherapeutics, Inc. | 252.69 Million USD | -68.036% |
| ADMA Biologics, Inc. | 193.97 Million USD | -118.905% |
| Clene Inc. | 38.95 Million USD | -990.149% |
| Recursion Pharmaceuticals, Inc. | 190.26 Million USD | -123.177% |
| Aptose Biosciences Inc. | 15.8 Million USD | -2586.014% |
| ZyVersa Therapeutics, Inc. | 11.03 Million USD | -3746.341% |
| Soligenix, Inc. | 7.27 Million USD | -5736.833% |
| Century Therapeutics, Inc. | 175.94 Million USD | -141.345% |
| Kura Oncology, Inc. | 51.66 Million USD | -721.927% |
| Surrozen, Inc. | 8.14 Million USD | -5113.309% |
| TScan Therapeutics, Inc. | 121.28 Million USD | -250.113% |
| Ocean Biomedical, Inc. | 6.61 Million USD | -6320.219% |
| CytomX Therapeutics, Inc. | 252.59 Million USD | -68.103% |
| Autolus Therapeutics plc | 263.9 Million USD | -60.899% |
| Mineralys Therapeutics, Inc. | 10.48 Million USD | -3950.983% |
| Eterna Therapeutics Inc. | 46.89 Million USD | -805.401% |
| Caribou Biosciences, Inc. | 72.56 Million USD | -485.148% |
| GRI Bio, Inc. | 2.69 Million USD | -15644.308% |
| Xenetic Biosciences, Inc. | 809.58 Thousand USD | -52349.588% |
| Janux Therapeutics, Inc. | 36.05 Million USD | -1077.614% |
| INmune Bio, Inc. | 18.86 Million USD | -2151.214% |
| Heron Therapeutics, Inc. | 256.47 Million USD | -65.559% |
| SAB Biotherapeutics, Inc. | 26.64 Million USD | -1493.826% |
| Pasithea Therapeutics Corp. | 2.71 Million USD | -15520.33% |
| Tenax Therapeutics, Inc. | 3.58 Million USD | -11739.443% |
| Jaguar Health, Inc. | 45.86 Million USD | -825.793% |
| Entero Therapeutics, Inc. | 3.28 Million USD | -12844.804% |
| Milestone Pharmaceuticals Inc. | 58.45 Million USD | -626.412% |
| Clearside Biomedical, Inc. | 49.93 Million USD | -750.439% |
| Atara Biotherapeutics, Inc. | 264.73 Million USD | -60.396% |
| Coherus BioSciences, Inc. | 823.02 Million USD | 48.407% |
| Verastem, Inc. | 71.18 Million USD | -496.508% |
| Pliant Therapeutics, Inc. | 38.57 Million USD | -1000.69% |
| Histogen Inc. | 5.69 Million USD | -7353.467% |
| Aprea Therapeutics, Inc. | 4.38 Million USD | -9582.222% |
| ACADIA Pharmaceuticals Inc. | 317.2 Million USD | -33.866% |
| Surrozen, Inc. | 8.14 Million USD | -5113.309% |
| Organovo Holdings, Inc. | 2.74 Million USD | -15352.111% |
| Lixte Biotechnology Holdings, Inc. | 313.85 Thousand USD | -135191.756% |
| Cadrenal Therapeutics, Inc. Common Stock | 826.87 Thousand USD | -51252.865% |
| Centessa Pharmaceuticals plc | 126.72 Million USD | -235.075% |
| Hepion Pharmaceuticals, Inc. | 10.81 Million USD | -3826.763% |
| BioRestorative Therapies, Inc. | 2.6 Million USD | -16185.685% |
| Kronos Bio, Inc. | 54.2 Million USD | -683.425% |
| Turnstone Biologics Corp. | 14.14 Million USD | -2901.301% |
| Synaptogenix, Inc. | 5.52 Million USD | -7579.291% |
| Tiziana Life Sciences Ltd | 6.64 Million USD | -6287.244% |
| Entrada Therapeutics, Inc. | 226.83 Million USD | -87.198% |
| Aurinia Pharmaceuticals Inc. | 170.1 Million USD | -149.62% |
| Exelixis, Inc. | 678.44 Million USD | 37.412% |
| Nurix Therapeutics, Inc. | 164.04 Million USD | -158.844% |
| Apellis Pharmaceuticals, Inc. | 594.2 Million USD | 28.54% |
| Jasper Therapeutics, Inc. | 14.67 Million USD | -2793.322% |
| ESSA Pharma Inc. | 3.49 Million USD | -12049.224% |
| TNF Pharmaceuticals, Inc. | 5.08 Million USD | -8244.569% |
| Avid Bioservices, Inc. | 275.66 Million USD | -54.035% |
| Insmed Incorporated | 1.66 Billion USD | 74.447% |
| MediWound Ltd. | 27.18 Million USD | -1461.864% |
| OmniAb, Inc. | 87.4 Million USD | -385.84% |
| Alector, Inc. | 487.66 Million USD | 12.928% |
| Seres Therapeutics, Inc. | 403.45 Million USD | -5.247% |
| Zai Lab Limited | 240.17 Million USD | -76.796% |
| AlloVir, Inc. | 45.01 Million USD | -843.294% |
| Revance Therapeutics, Inc. | 630.05 Million USD | 32.606% |
| ORIC Pharmaceuticals, Inc. | 30.59 Million USD | -1287.751% |
| Aura Biosciences, Inc. | 29.22 Million USD | -1352.848% |
| Immunic, Inc. | 25.36 Million USD | -1573.857% |
| Tarsus Pharmaceuticals, Inc. | 69.23 Million USD | -513.299% |
| Veracyte, Inc. | 93.71 Million USD | -353.082% |
| InMed Pharmaceuticals Inc. | 2.61 Million USD | -16127.63% |
| FibroGen, Inc. | 585.72 Million USD | 27.505% |
| SeaStar Medical Holding Corporation | 17.38 Million USD | -2342.754% |
| Catalyst Pharmaceuticals, Inc. | 84.02 Million USD | -405.348% |
| Adial Pharmaceuticals, Inc. | 653.07 Thousand USD | -64919.079% |
| Sonnet BioTherapeutics Holdings, Inc. | 5.65 Million USD | -7408.216% |
| Cyclacel Pharmaceuticals, Inc. | 8.19 Million USD | -5079.605% |
| Amylyx Pharmaceuticals, Inc. | 84.02 Million USD | -405.372% |
| Fortrea Holdings Inc. | 2.61 Billion USD | 83.783% |
| KalVista Pharmaceuticals, Inc. | 28.82 Million USD | -1373.263% |
| XBiotech Inc. | 8.39 Million USD | -4956.854% |
| Jasper Therapeutics, Inc. | 14.67 Million USD | -2793.322% |
| Keros Therapeutics, Inc. | 37.81 Million USD | -1022.987% |
| SELLAS Life Sciences Group, Inc. | 14.37 Million USD | -2853.084% |
| Lyra Therapeutics, Inc. | 53.18 Million USD | -698.466% |
| Foghorn Therapeutics Inc. | 363.1 Million USD | -16.942% |
| Agenus Inc. | 462.29 Million USD | 8.149% |
| Y-mAbs Therapeutics, Inc. | 26.88 Million USD | -1479.467% |
| Theravance Biopharma, Inc. | 169 Million USD | -151.251% |
| Ultragenyx Pharmaceutical Inc. | 1.21 Billion USD | 65.069% |
| Metagenomi, Inc. Common Stock | 500.42 Million USD | 15.147% |
| BioCryst Pharmaceuticals, Inc. | 972.48 Million USD | 56.336% |
| Gain Therapeutics, Inc. | 6.03 Million USD | -6940.565% |
| C4 Therapeutics, Inc. | 130.33 Million USD | -225.789% |
| Creative Medical Technology Holdings, Inc. | 371.39 Thousand USD | -114232.488% |
| Chemomab Therapeutics Ltd. | 5.15 Million USD | -8138.679% |
| Lantern Pharma Inc. | 2.73 Million USD | -15399.025% |
| Eledon Pharmaceuticals, Inc. | 42.47 Million USD | -899.703% |
| Ainos, Inc. | 7.39 Million USD | -5642.645% |
| Pluri Inc. | 34.11 Million USD | -1144.794% |
| Prothena Corporation plc | 135.01 Million USD | -214.497% |
| Adaptimmune Therapeutics plc | 243.1 Million USD | -74.668% |
| Rallybio Corporation | 9.43 Million USD | -4400.042% |
| Kodiak Sciences Inc. | 213.59 Million USD | -98.802% |
| Cue Biopharma, Inc. | 24.44 Million USD | -1637.059% |
| MeiraGTx Holdings plc | 319.99 Million USD | -32.699% |
| Annexon, Inc. | 47.11 Million USD | -801.193% |
| Assembly Biosciences, Inc. | 96.37 Million USD | -340.609% |
| Moderna, Inc. | 4.57 Billion USD | 90.713% |
| Cocrystal Pharma, Inc. | 4.87 Million USD | -8610.236% |
| Cidara Therapeutics, Inc. | 76.74 Million USD | -453.328% |
| Blueprint Medicines Corporation | 918.64 Million USD | 53.777% |
| Immix Biopharma, Inc. | 3.72 Million USD | -11309.155% |
| CalciMedica, Inc. | 4.02 Million USD | -10441.807% |
| Monte Rosa Therapeutics, Inc. | 124.5 Million USD | -241.05% |
| Scholar Rock Holding Corporation | 85.81 Million USD | -394.802% |
| Wave Life Sciences Ltd. | 227.44 Million USD | -86.693% |
| Sana Biotechnology, Inc. | 277.79 Million USD | -52.856% |
| Elicio Therapeutics, Inc. | 15.77 Million USD | -2592.094% |
| Adlai Nortye Ltd. American Depositary Shares | 50.78 Million USD | -736.104% |
| Nutriband Inc. | 1.07 Million USD | -39256.43% |
| Protara Therapeutics, Inc. | 10.63 Million USD | -3893.454% |
| Vor Biopharma Inc. | 59.1 Million USD | -618.435% |
| Roivant Sciences Ltd. | 773.95 Million USD | 45.136% |
| Alkermes plc | 933.53 Million USD | 54.514% |
| ProKidney Corp. | 29.21 Million USD | -1353.395% |
| Applied Therapeutics, Inc. | 71.97 Million USD | -489.928% |
| Arcellx, Inc. | 339.75 Million USD | -24.981% |
| BridgeBio Pharma, Inc. | 1.88 Billion USD | 77.52% |
| Tango Therapeutics, Inc. | 149.45 Million USD | -184.107% |
| Galectin Therapeutics Inc. | 88.44 Million USD | -380.121% |
| Atai Life Sciences N.V. | 49.16 Million USD | -763.724% |
| Renovaro Biosciences Inc. | 31.15 Million USD | -1263.058% |
| Aerovate Therapeutics, Inc. | 17.96 Million USD | -2264.013% |
| MediciNova, Inc. | 3.89 Million USD | -10811.428% |
| Praxis Precision Medicines, Inc. | 18.27 Million USD | -2223.015% |
| Cardio Diagnostics Holdings, Inc. | 1.5 Million USD | -28128.455% |
| GeoVax Labs, Inc. | 3.51 Million USD | -11963.59% |
| Axsome Therapeutics, Inc. | 397.25 Million USD | -6.888% |
| Biomea Fusion, Inc. | 30.69 Million USD | -1283.591% |
| RenovoRx, Inc. | 4.46 Million USD | -9407.927% |
| Cullinan Oncology, Inc. | 31.2 Million USD | -1260.931% |
| Geron Corporation | 146.12 Million USD | -190.586% |
| NRx Pharmaceuticals, Inc. | 19.04 Million USD | -2129.231% |
| 4D Molecular Therapeutics, Inc. | 32.06 Million USD | -1224.384% |
| Dyne Therapeutics, Inc. | 73.79 Million USD | -475.449% |
| Kiniksa Pharmaceuticals, Ltd. | 87.48 Million USD | -385.379% |
| Royalty Pharma plc | 6.29 Billion USD | 93.257% |
| Ventyx Biosciences, Inc. | 33.77 Million USD | -1157.4% |
| Imunon, Inc. | 8.53 Million USD | -4877.758% |
| BioAtla, Inc. | 48.98 Million USD | -766.827% |
| Allogene Therapeutics, Inc. | 130.6 Million USD | -225.123% |
| Larimar Therapeutics, Inc. | 14.21 Million USD | -2887.154% |
| Mersana Therapeutics, Inc. | 189.15 Million USD | -124.483% |
| Structure Therapeutics Inc. | 29.05 Million USD | -1361.65% |
| 89bio, Inc. | 59.96 Million USD | -608.143% |
| Kezar Life Sciences, Inc. | 33.66 Million USD | -1161.322% |
| aTyr Pharma, Inc. | 31.59 Million USD | -1243.874% |
| Aligos Therapeutics, Inc. | 61.82 Million USD | -586.838% |
| Viridian Therapeutics, Inc. | 48.4 Million USD | -777.286% |
| EyeGate Pharmaceuticals, Inc. | 8.15 Million USD | -5104.99% |
| Akari Therapeutics, Plc | 4.58 Million USD | -9163.176% |
| Tevogen Bio Holdings Inc. | 17.73 Million USD | -2294.524% |
| Halozyme Therapeutics, Inc. | 1.64 Billion USD | 74.257% |
| Lexicon Pharmaceuticals, Inc. | 136.31 Million USD | -211.493% |
| Liquidia Corporation | 73.13 Million USD | -480.579% |
| Entera Bio Ltd. | 1.37 Million USD | -30692.168% |
| GH Research PLC | 6.7 Million USD | -6236.726% |
| Vericel Corporation | 127.7 Million USD | -232.504% |
| Arbutus Biopharma Corporation | 38.38 Million USD | -1006.281% |
| Xencor, Inc. | 283.55 Million USD | -49.748% |
| 60 Degrees Pharmaceuticals, Inc. | 2.98 Million USD | -14122.044% |
| Pasithea Therapeutics Corp. | 2.71 Million USD | -15520.33% |
| Coeptis Therapeutics Holdings, Inc. | 3.75 Million USD | -11201.833% |
| Vaxcyte, Inc. | 167.44 Million USD | -153.584% |
| Xenon Pharmaceuticals Inc. | 36.87 Million USD | -1051.46% |
| Vanda Pharmaceuticals Inc. | 103.53 Million USD | -310.146% |
| Lexaria Bioscience Corp. | 403.9 Thousand USD | -105028.891% |
| Portage Biotech Inc. | 4.45 Million USD | -9442.112% |
| Cardio Diagnostics Holdings, Inc. | 1.5 Million USD | -28128.455% |
| Olema Pharmaceuticals, Inc. | 23.05 Million USD | -1742.187% |
| OncoCyte Corporation | 49.29 Million USD | -761.341% |
| Qualigen Therapeutics, Inc. | 4.13 Million USD | -10164.54% |
| Processa Pharmaceuticals, Inc. | 797.48 Thousand USD | -53145.457% |
| Purple Biotech Ltd. | 10 Million USD | -4144.118% |
| Tempest Therapeutics, Inc. | 24.83 Million USD | -1609.781% |
| Sol-Gel Technologies Ltd. | 6.64 Million USD | -6292.052% |
| Rhythm Pharmaceuticals, Inc. | 162.98 Million USD | -160.528% |
| CollPlant Biotechnologies Ltd. | 5.78 Million USD | -7238.818% |
| Moleculin Biotech, Inc. | 12.14 Million USD | -3396.574% |
| United Therapeutics Corporation | 1.18 Billion USD | 64.082% |
| HilleVax, Inc. | 78.9 Million USD | -438.119% |
| Silo Pharma, Inc. | 1.56 Million USD | -26958.696% |
| Telomir Pharmaceuticals, Inc. Common Stock | 1.33 Million USD | -31693.609% |
| Pharming Group N.V. | 244.07 Million USD | -73.974% |
| Tharimmune, Inc. | 1.81 Million USD | -23294.669% |
| Genprex, Inc. | 3.25 Million USD | -12948.459% |
| Apogee Therapeutics, Inc. | 21.49 Million USD | -1875.822% |
| Neumora Therapeutics, Inc. Common Stock | 27.11 Million USD | -1465.78% |
| Pyxis Oncology, Inc. | 48.02 Million USD | -784.228% |
| XTL Biopharmaceuticals Ltd. | 206 Thousand USD | -206028.155% |
| Virios Therapeutics, Inc. | 358.54 Thousand USD | -118328.774% |
| OKYO Pharma Limited | 7.42 Million USD | -5622.043% |
| Savara Inc. | 37.19 Million USD | -1041.708% |
| Windtree Therapeutics, Inc. | 29.01 Million USD | -1363.464% |
| Curis, Inc. | 57.61 Million USD | -637.041% |
| Carmell Therapeutics Corporation | 39.19 Million USD | -983.23% |
| Achieve Life Sciences, Inc. | 20.81 Million USD | -1939.598% |
| BeiGene, Ltd. | 2.23 Billion USD | 80.99% |
| Protagonist Therapeutics, Inc. | 21.27 Million USD | -1895.976% |
| Erasca, Inc. | 78.61 Million USD | -440.159% |
| Protagenic Therapeutics, Inc. | 655.25 Thousand USD | -64703.16% |
| Protagenic Therapeutics, Inc. | 655.25 Thousand USD | -64703.16% |
| Vincerx Pharma, Inc. | 6.99 Million USD | -5970.393% |
| Fresh Tracks Therapeutics, Inc. | 1.65 Million USD | -25541.546% |
| Acrivon Therapeutics, Inc. Common Stock | 17.07 Million USD | -2387.545% |
| Celldex Therapeutics, Inc. | 36.45 Million USD | -1064.758% |
| Cogent Biosciences, Inc. | 55.63 Million USD | -663.232% |
| Adicet Bio, Inc. | 37.12 Million USD | -1043.922% |
| Amicus Therapeutics, Inc. | 617.7 Million USD | 31.258% |
| Aditxt, Inc. | 28.53 Million USD | -1388.261% |
| Adagene Inc. | 45.16 Million USD | -840.071% |
| Estrella Immunopharma, Inc. | 180.7 Thousand USD | -234887.078% |
| Quantum-Si incorporated | 26.63 Million USD | -1494.473% |
| Acurx Pharmaceuticals, Inc. | 3.04 Million USD | -13856.702% |
| Voyager Therapeutics, Inc. | 114.96 Million USD | -269.364% |
| Compugen Ltd. | 55.77 Million USD | -661.316% |
| Generation Bio Co. | 171.63 Million USD | -147.407% |
| Astria Therapeutics, Inc. | 11.55 Million USD | -3576.398% |
| Black Diamond Therapeutics, Inc. | 41.83 Million USD | -915.094% |
| Invivyd, Inc. | 51.71 Million USD | -721.117% |
| Relay Therapeutics, Inc. | 91.97 Million USD | -361.663% |
| Quoin Pharmaceuticals, Ltd. | 6.5 Million USD | -6427.404% |
| Spero Therapeutics, Inc. | 75.49 Million USD | -462.446% |
| Artelo Biosciences, Inc. | 1.02 Million USD | -41489.03% |
| 2seventy bio, Inc. | 310.12 Million USD | -36.92% |
| Instil Bio, Inc. | 99.8 Million USD | -325.471% |
| Capricor Therapeutics, Inc. | 36.13 Million USD | -1075.174% |
| Elevai Labs, Inc. Common Stock | 1.36 Million USD | -31057.243% |
| GeoVax Labs, Inc. | 3.51 Million USD | -11963.59% |
| Citius Pharmaceuticals, Inc. | 12.17 Million USD | -3386.336% |
| Relmada Therapeutics, Inc. | 12.19 Million USD | -3382.009% |
| ALX Oncology Holdings Inc. | 52.84 Million USD | -703.588% |
| Vir Biotechnology, Inc. | 369.85 Million USD | -14.809% |
| Evaxion Biotech A/S | 17.61 Million USD | -2310.243% |
| Ocular Therapeutix, Inc. | 160.92 Million USD | -163.858% |
| Verve Therapeutics, Inc. | 153.18 Million USD | -177.195% |
| Tyra Biosciences, Inc. | 21.59 Million USD | -1866.307% |
| Cingulate Inc. | 10.36 Million USD | -3998.345% |
| Galmed Pharmaceuticals Ltd. | 2.75 Million USD | -15340.873% |
| Unity Biotechnology, Inc. | 37.29 Million USD | -1038.646% |
| Connect Biopharma Holdings Limited | 24.84 Million USD | -1608.817% |
| Clearmind Medicine Inc. | 3.61 Million USD | -11662.412% |
| Bolt Biotherapeutics, Inc. | 47.04 Million USD | -802.63% |
| CERo Therapeutics Holdings, Inc. | 22.75 Million USD | -1765.681% |
| Viking Therapeutics, Inc. | 20.07 Million USD | -2015.61% |
| Madrigal Pharmaceuticals, Inc. | 235.21 Million USD | -80.527% |
| ImmunityBio, Inc. | 1.09 Billion USD | 61.058% |
| Korro Bio, Inc. | 51.75 Million USD | -720.498% |
| Kineta, Inc. | 7.22 Million USD | -5779.59% |
| BioVie Inc. | 9.7 Million USD | -4276.606% |
| Codexis, Inc. | 49.94 Million USD | -750.166% |
| Celularity Inc. | 102.92 Million USD | -312.541% |
| Aileron Therapeutics, Inc. | 112.39 Million USD | -277.783% |
| Crinetics Pharmaceuticals, Inc. | 96.24 Million USD | -341.182% |
| Virax Biolabs Group Limited | 345.19 Thousand USD | -122910.249% |
| Cibus, Inc. | 206.11 Million USD | -106.011% |
| IN8bio, Inc. | 8.77 Million USD | -4740.675% |
| Adverum Biotechnologies, Inc. | 89.54 Million USD | -374.223% |
| Avalo Therapeutics, Inc. | 13.68 Million USD | -3001.936% |
| Ionis Pharmaceuticals, Inc. | 2.6 Billion USD | 83.69% |
| Eyenovia, Inc. | 19.78 Million USD | -2046.704% |
| Puma Biotechnology, Inc. | 177.08 Million USD | -139.784% |
| Conduit Pharmaceuticals Inc. | 7.68 Million USD | -5428.239% |
| Elevation Oncology, Inc. | 34.28 Million USD | -1138.621% |
| Xilio Therapeutics, Inc. | 24.09 Million USD | -1661.998% |
| Cardiff Oncology, Inc. | 11.89 Million USD | -3468.869% |
| Enanta Pharmaceuticals, Inc. | 245.54 Million USD | -72.935% |
| Regulus Therapeutics Inc. | 9.56 Million USD | -4340.28% |
| Moolec Science SA | 13.94 Million USD | -2944.913% |
| Acumen Pharmaceuticals, Inc. | 43.15 Million USD | -884.019% |
| LAVA Therapeutics N.V. | 50.53 Million USD | -740.307% |
| Atea Pharmaceuticals, Inc. | 39.77 Million USD | -967.538% |
| Compass Therapeutics, Inc. | 8.33 Million USD | -4993.247% |
| Greenwich LifeSciences, Inc. | 294.4 Thousand USD | -144130.756% |
| TFF Pharmaceuticals, Inc. | 2.46 Million USD | -17159.16% |
| Humacyte, Inc. | 114.67 Million USD | -270.278% |
| PMV Pharmaceuticals, Inc. | 26.46 Million USD | -1504.595% |
| Avenue Therapeutics, Inc. | 1.19 Million USD | -35403.679% |
| Genelux Corporation | 8.42 Million USD | -4943.04% |
| Trevi Therapeutics, Inc. | 6.85 Million USD | -6093.466% |
| Notable Labs, Ltd. | 4.42 Million USD | -9491.687% |
| Immunovant, Inc. | 48.95 Million USD | -767.376% |
| Quantum-Si incorporated | 26.63 Million USD | -1494.473% |
| DiaMedica Therapeutics Inc. | 3.1 Million USD | -13584.306% |
| Vera Therapeutics, Inc. | 73.86 Million USD | -474.896% |
| Acasti Pharma Inc. | 11.55 Million USD | -3574.171% |
| MiNK Therapeutics, Inc. | 22.6 Million USD | -1778.225% |
| Soleno Therapeutics, Inc. | 23.18 Million USD | -1731.539% |
| PepGen Inc. | 34.63 Million USD | -1126.138% |
| Nuvectis Pharma, Inc. | 6.98 Million USD | -5979.954% |
| BriaCell Therapeutics Corp. | 8.55 Million USD | -4862.188% |
| Immuneering Corporation | 12 Million USD | -3436.071% |
| Lixte Biotechnology Holdings, Inc. | 313.85 Thousand USD | -135191.756% |
| Belite Bio, Inc | 4.21 Million USD | -9983.686% |
| XOMA Corporation | 145.58 Million USD | -191.677% |
| ARS Pharmaceuticals, Inc. | 2.42 Million USD | -17388.633% |
| Bionomics Limited | 10.15 Million USD | -4079.896% |
| Alpha Tau Medical Ltd. | 22.91 Million USD | -1753.201% |
| uniQure N.V. | 624.01 Million USD | 31.953% |
| Estrella Immunopharma, Inc. | 180.7 Thousand USD | -234887.078% |
| Poseida Therapeutics, Inc. | 170.18 Million USD | -149.509% |
| Forte Biosciences, Inc. | 3.66 Million USD | -11482.761% |
| Anebulo Pharmaceuticals, Inc. | 260.58 Thousand USD | -162851.536% |
| Enlivex Therapeutics Ltd. | 6.74 Million USD | -6193.523% |
| Conduit Pharmaceuticals Inc. | 7.68 Million USD | -5428.239% |
| SeaStar Medical Holding Corporation | 17.38 Million USD | -2342.754% |
| FibroBiologics, Inc. Common Stock | 10.56 Million USD | -3918.017% |
| Altimmune, Inc. | 16.54 Million USD | -2467.1% |
| LENZ Therapeutics, Inc. | 4.87 Million USD | -8612.023% |
| Alpha Tau Medical Ltd. | 22.91 Million USD | -1753.201% |
| Peak Bio, Inc. | 20.75 Million USD | -1946.049% |
| Zevra Therapeutics, Inc. | 110.46 Million USD | -284.404% |
| Benitec Biopharma Inc. | 4.96 Million USD | -8457.517% |
| Spyre Therapeutics, Inc. | 157.84 Million USD | -169.017% |
| NKGen Biotech, Inc. Common Stock | 75.17 Million USD | -464.855% |
| Zura Bio Limited | 21.29 Million USD | -1894.289% |
| PolyPid Ltd. | 17.46 Million USD | -2330.868% |
| NKGen Biotech, Inc. Warrants | 75.17 Million USD | -464.855% |
| argenx SE | 444.95 Million USD | 4.568% |
| Immunome, Inc. | 28.65 Million USD | -1381.694% |
| Verona Pharma plc | 58.84 Million USD | -621.646% |
| enGene Holdings Inc. Warrants | 14.47 Million USD | -2833.905% |
| Shattuck Labs, Inc. | 14.85 Million USD | -2757.689% |
| CervoMed Inc. | 2.59 Million USD | -16258.451% |
| Plus Therapeutics, Inc. | 12.73 Million USD | -3234.045% |
| Dianthus Therapeutics, Inc. | 10.53 Million USD | -3930.603% |
| Moolec Science SA | 13.94 Million USD | -2944.913% |
| Enveric Biosciences, Inc. | 2.34 Million USD | -18019.192% |
| Design Therapeutics, Inc. | 11.95 Million USD | -3451.556% |
| Leap Therapeutics, Inc. | 12.68 Million USD | -3247.714% |
| Seelos Therapeutics, Inc. | 38.92 Million USD | -990.793% |
| Achilles Therapeutics plc | 19.08 Million USD | -2124.676% |
| CERo Therapeutics Holdings, Inc. | 22.75 Million USD | -1765.681% |
| CG Oncology, Inc. Common stock | 14.51 Million USD | -2826.221% |
| Fractyl Health, Inc. Common Stock | 401.27 Million USD | -5.819% |
| Rani Therapeutics Holdings, Inc. | 32.47 Million USD | -1207.622% |
| MoonLake Immunotherapeutics | 13.04 Million USD | -3154.049% |
| Tourmaline Bio, Inc. | 5.25 Million USD | -7983.457% |
| Beam Therapeutics Inc. | 478.38 Million USD | 11.238% |
| Mirum Pharmaceuticals, Inc. | 397.95 Million USD | -6.703% |
| AEON Biopharma, Inc. | 159.88 Million USD | -165.574% |
| Aadi Bioscience, Inc. | 27.22 Million USD | -1459.512% |
| Enliven Therapeutics, Inc. | 25.96 Million USD | -1535.623% |
| Kiora Pharmaceuticals, Inc. | 7.6 Million USD | -5485.529% |
| NeurAxis, Inc. | 1.91 Million USD | -22099.788% |
| Iovance Biotherapeutics, Inc. | 195.73 Million USD | -116.935% |
| Lumos Pharma, Inc. | 13.33 Million USD | -3084.76% |
| Opiant Pharmaceuticals, Inc. | 23.58 Million USD | -1700.17% |
| Palisade Bio, Inc. | 2.73 Million USD | -15402.884% |
| Nutriband Inc. | 1.07 Million USD | -39256.43% |
| Taysha Gene Therapies, Inc. | 192.05 Million USD | -121.093% |
| Neurogene Inc. | 36.54 Million USD | -1061.794% |
| Kintara Therapeutics, Inc. | 2.44 Million USD | -17267.035% |
| CARGO Therapeutics, Inc. Common Stock | 47.65 Million USD | -791.131% |
| Athira Pharma, Inc. | 30.05 Million USD | -1312.729% |
| HCW Biologics Inc. | 15.05 Million USD | -2721.058% |
| XOMA Corporation | 145.58 Million USD | -191.677% |
| Nektar Therapeutics | 267.04 Million USD | -59.008% |
| Arvinas, Inc. | 644.6 Million USD | 34.126% |
| Tevogen Bio Holdings Inc. | 17.73 Million USD | -2294.524% |
| Merus N.V. | 102.15 Million USD | -315.683% |
| Omega Therapeutics, Inc. | 146.35 Million USD | -190.143% |
| Quince Therapeutics, Inc. | 95.12 Million USD | -346.409% |
| Rezolute, Inc. | 11.73 Million USD | -3518.749% |
| Clene Inc. | 38.95 Million USD | -990.149% |
| Indaptus Therapeutics, Inc. | 2.84 Million USD | -14812.797% |
| BeyondSpring Inc. | 48.26 Million USD | -779.703% |
| Synlogic, Inc. | 32.89 Million USD | -1190.847% |
| Allarity Therapeutics, Inc. | 14.61 Million USD | -2805.796% |
| Phio Pharmaceuticals Corp. | 1.63 Million USD | -25886.781% |
| Peak Bio, Inc. | 20.75 Million USD | -1946.049% |
| Werewolf Therapeutics, Inc. | 63.45 Million USD | -569.131% |
| Krystal Biotech, Inc. | 39.71 Million USD | -969.205% |
| Karyopharm Therapeutics Inc. | 376.64 Million USD | -12.739% |
| SpringWorks Therapeutics, Inc. | 99.56 Million USD | -326.462% |
| Lipella Pharmaceuticals Inc. | 432.72 Thousand USD | -98027.684% |
| MannKind Corporation | 721.36 Million USD | 41.136% |
| Ikena Oncology, Inc. | 22.33 Million USD | -1801.16% |
| Cyclerion Therapeutics, Inc. | 2.08 Million USD | -20255.896% |
| Gyre Therapeutics, Inc. | 102.59 Million USD | -313.904% |
| Gossamer Bio, Inc. | 249.14 Million USD | -70.431% |
| CohBar, Inc. | 1.03 Million USD | -40980.533% |
| Cognition Therapeutics, Inc. | 10.68 Million USD | -3872.533% |
| NRx Pharmaceuticals, Inc. | 19.04 Million USD | -2129.231% |
| Legend Biotech Corporation | 589.93 Million USD | 28.022% |
| Mural Oncology plc | 37.92 Million USD | -1019.553% |
| Disc Medicine, Inc. | 22.87 Million USD | -1756.28% |
| Champions Oncology, Inc. | 28.03 Million USD | -1414.621% |
| REGENXBIO Inc. | 262.22 Million USD | -61.929% |
| Ensysce Biosciences, Inc. | 3.35 Million USD | -12540.057% |
| Anavex Life Sciences Corp. | 12.53 Million USD | -3287.777% |
| Cellectar Biosciences, Inc. | 13.43 Million USD | -3061.374% |
| Edgewise Therapeutics, Inc. | 21.2 Million USD | -1902.471% |
| Vaxart, Inc. | 34.02 Million USD | -1147.976% |
| PharmaCyte Biotech, Inc. | 20.38 Million USD | -1982.586% |
| Aldeyra Therapeutics, Inc. | 28.53 Million USD | -1388.244% |
| Cellectis S.A. | 249.57 Million USD | -70.139% |
| Longeveron Inc. | 5.33 Million USD | -7856.23% |
| Repare Therapeutics Inc. | 41.81 Million USD | -915.385% |
| Sarepta Therapeutics, Inc. | 2.4 Billion USD | 82.346% |
| Inozyme Pharma, Inc. | 60.36 Million USD | -603.393% |
| Revolution Medicines, Inc. | 262.39 Million USD | -61.825% |
| Nymox Pharmaceutical Corporation | 2.1 Million USD | -20053.014% |
| Third Harmonic Bio, Inc. | 8.62 Million USD | -4822.606% |
| ArriVent BioPharma, Inc. Common Stock | 11.8 Million USD | -3498.204% |
| AN2 Therapeutics, Inc. | 14.04 Million USD | -2923.741% |
| Anixa Biosciences, Inc. | 2.15 Million USD | -19640.772% |
| Vertex Pharmaceuticals Incorporated | 5.14 Billion USD | 91.755% |
| Denali Therapeutics Inc. | 122.96 Million USD | -245.327% |
| Revelation Biosciences, Inc. | 5.56 Million USD | -7530.406% |
| Veru Inc. | 32.81 Million USD | -1194.084% |
| Corvus Pharmaceuticals, Inc. | 6.86 Million USD | -6081.744% |
| Cingulate Inc. | 10.36 Million USD | -3998.345% |
| Passage Bio, Inc. | 39.26 Million USD | -981.514% |
| Context Therapeutics Inc. | 4.19 Million USD | -10030.078% |
| Exicure, Inc. | 8.54 Million USD | -4866.944% |
| Day One Biopharmaceuticals, Inc. | 29.5 Million USD | -1339.013% |
| Oramed Pharmaceuticals Inc. | 10.48 Million USD | -3949.437% |
| Scinai Immunotherapeutics Ltd. | 22.04 Million USD | -1826.519% |
| Nuvalent, Inc. | 31.82 Million USD | -1234.331% |
| ABVC BioPharma, Inc. | 6.36 Million USD | -6574.77% |
| Carisma Therapeutics, Inc. | 63.02 Million USD | -573.771% |
| Unicycive Therapeutics, Inc. | 18 Million USD | -2259.022% |
| OmniAb, Inc. | 87.4 Million USD | -385.84% |
| Anew Medical, Inc. | 8.24 Million USD | -5052.079% |
| Fennec Pharmaceuticals Inc. | 38.28 Million USD | -1008.995% |
| Lipocine Inc. | 2.63 Million USD | -16035.405% |
| Lexeo Therapeutics, Inc. Common Stock | 26.27 Million USD | -1516.261% |
| Nautilus Biotechnology, Inc. | 40.21 Million USD | -955.963% |
| SAB Biotherapeutics, Inc. | 26.64 Million USD | -1493.826% |
| G1 Therapeutics, Inc. | 86.15 Million USD | -392.866% |
| Bellerophon Therapeutics, Inc. | 5.4 Million USD | -7761.951% |
| Sage Therapeutics, Inc. | 82.74 Million USD | -413.159% |
| Ocugen, Inc. | 23.98 Million USD | -1670.521% |
| Mind Medicine (MindMed) Inc. | 46.4 Million USD | -815.0% |
| Q32 Bio Inc. | 233.12 Million USD | -82.142% |
| Brainstorm Cell Therapeutics Inc. | 9.06 Million USD | -4583.697% |
| Alumis Inc. Common Stock | 53.5 Million USD | -693.66% |
| Equillium, Inc. | 27.95 Million USD | -1418.847% |
| Kyverna Therapeutics, Inc. | 206.59 Million USD | -105.537% |
| Coya Therapeutics, Inc. | 5.62 Million USD | -7446.637% |
| CNS Pharmaceuticals, Inc. | 6.13 Million USD | -6823.63% |
| Dominari Holdings Inc. | 4.63 Million USD | -9061.251% |
| Edesa Biotech, Inc. | 1.84 Million USD | -22956.878% |
| vTv Therapeutics Inc. | 29.56 Million USD | -1336.142% |
| Bio-Techne Corporation | 744.34 Million USD | 42.953% |
| Agios Pharmaceuticals, Inc. | 126.09 Million USD | -236.739% |
| Harmony Biosciences Holdings, Inc. | 344.45 Million USD | -23.274% |
| Prelude Therapeutics Incorporated | 40.57 Million USD | -946.516% |
| Candel Therapeutics, Inc. | 28.95 Million USD | -1366.395% |
| iTeos Therapeutics, Inc. | 92.36 Million USD | -359.749% |
| Nkarta, Inc. | 105.6 Million USD | -302.106% |
| BioCardia, Inc. | 4.59 Million USD | -9151.068% |
| Iterum Therapeutics plc | 32.66 Million USD | -1200.055% |